NMPA accepts Akeso’s supplemental New Drug Application for gumokimab to treat active ankylosing spondylitis: Hong Kong Wednesday, January 21, 2026, 12:00 Hrs [IST] Akeso Inc, a ...
This week's report explores the pharmaceutical industry’s evolution toward resilient, scalable systems that prioritize ...
Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing ...
A look at the clinical progress of anti-Aβ monoclonal antibodies and how precision delivery is shaping the next generation of ...
ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...
AAX Biotech, a biotechnology company specialising in antibody therapeutics, and Vascurie, a biopharmaceutical company ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line ...
Key market opportunities in the antibody optimization service industry include addressing rising chronic and complex diseases ...
Immunomic Therapeutics, Inc. ("ITI"), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ('Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...
BOSTON, Jan. 20, 2026) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results